Devy Deliyanti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2581495/publications.pdf Version: 2024-02-01



Πενν Πειινλητι

1 Tetraspanin CD82 restrains phagocyte migration but supports macrophage activation. IScience, 2022, 25, 104520. 2 Angiotensin II and aldosterone activate retinal microglia. Experimental Eye Research, 2020, 191, 107902 3 The role of reactive oxygen species in the pathogenesis and treatment of retinal diseases. Experimental Eye Research, 2020, 201, 108255. 4 Lung and Eye Disease Develop Concurrently in Supplemental OxygenêC"Exposed Neonatal Mice. America Journal of Pathology, 2020, 190, 1801-1812. 5 Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101. 6 Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. 7 Preceives Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. 8 Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. 9 Endothelin-2 Injures the BloodâC"Retinal Barrier and Macroglial MļAller Cells. American Journal of Pathology, 2018, 188, 805-817. 10 Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. 11 Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy , 2018, 59, 815.	4.1 2. 2.6 2.6 can 3.8	5 19 35
 Angiotensin II and aldosterone activate retinal microglia. Experimental Eye Research, 2020, 191, 107902 The role of reactive oxygen species in the pathogenesis and treatment of retinal diseases. Experimental Eye Research, 2020, 201, 108255. Lung and Eye Disease Develop Concurrently in Supplemental Oxygenã€"Exposed Neonatal Mice. America Journal of Pathology, 2020, 190, 1801-1812. Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelm-2 Injures the Bloodã€"Retinal Barrier and Macroglial Müiller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy., 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8).Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EB0Medicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, 541-541. 	2. 2.6 2.6 can 3.8	19 35
 The role of reactive oxygen species in the pathogenesis and treatment of retinal diseases. Experimental Eye Research, 2020, 201, 108255. Lung and Eye Disease Develop Concurrently in Supplemental Oxygenã C"Exposed Neonatal Mice. America Journal of Pathology, 2020, 190, 1801-1812. Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelin-2 Injures the BloodáC"Retinal Barrier and Macroglial MÃV4ller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rets. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy. , 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	2.6 can 3.8 2.7	35
 Lung and Eye Disease Develop Concurrently in Supplemental Oxygenã E"Exposed Neonatal Mice. America Journal of Pathology, 2020, 190, 1801-1812. Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelin-2 Injures the Bloodâć "Retinal Barrier and Macroglial MļAller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy. , 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	an 3.8 2.7	0
 Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelin-2 Injures the Bloodáć^{en} Retinal Barrier and Macroglial MÅi/Aller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy., 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, 541-541. 	2.7	У
 Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Experimental Eye Research, 2019, 187, 107766. Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelin-2 Injures the Bloodâé^{ce}Retinal Barrier and Macroglial MÅi/Aller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy., 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, \$41-541. 		42
 Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580. Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. Endothelin-2 Injures the Blood–Retinal Barrier and Macroglial MÃI/aller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy. , 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	2.6	34
 8 Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells. Clinical and Experimental Ophthalmology, 2018, 46, 652-660. 9 Endothelin-2 Injures the Bloodâć"Retinal Barrier and Macroglial MÅI/Aller Cells. American Journal of Pathology, 2018, 188, 805-817. 10 Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. 11 Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy., 2018, 59, 815. 12 Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. 13 Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. 14 The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	3.6	16
 Endothelin-2 Injures the Blood–Retinal Barrier and Macroglial MÃ1/4ller Cells. American Journal of Pathology, 2018, 188, 805-817. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy. , 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VECF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	2.6	25
 Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats. Experimental Eye Research, 2018, 176, 1-9. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy., 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	3.8	17
 Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy. , 2018, 59, 815. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	2.6	9
 Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications, 2017, 8, 748. Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 		58
 Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination. EBioMedicine, 2017, 25, 122-135. The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41. 	12.8	63
The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies. Annals of Translational Medicine, 2016, 4, S41-S41.	6.1	27
	1.7	2
 Inhibition of the Nuclear Receptor RORÎ³ and Interleukin-17A Suppresses Neovascular Retinopathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1186-1196. 	2.4	41
A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy. Clinical Science, 2016, 130, 1375-1387.	4.3	27
 Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina. Journal of Neuroinflammation, 2015, 12, 136. 	7.2	65
18 Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. Journal of Autoimmunity, 2015, 61, 9-16.		41

Devy Deliyanti

#	Article	IF	CITATIONS
19	Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina. Experimental Eye Research, 2015, 136, 1-8.	2.6	38
20	Prorenin stimulates a proâ€angiogenic and proâ€inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 537-548.	1.9	22
21	FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS ONE, 2015, 10, e0134392.	2.5	14
22	Retinal Vasculopathy Is Reduced by Dietary Salt Restriction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2033-2041.	2.4	22
23	NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxidants and Redox Signaling, 2014, 20, 2726-2740.	5.4	104
24	Brain and retinal microglia in health and disease: An unrecognized target of the renin–angiotensin system. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 571-579.	1.9	32
25	The TACI Receptor Regulates T-Cell-Independent Marginal Zone B Cell Responses through Innate Activation-Induced Cell Death. Immunity, 2013, 39, 573-583.	14.3	58
26	Neovascularization Is Attenuated With Aldosterone Synthase Inhibition in Rats With Retinopathy. Hypertension, 2012, 59, 607-613.	2.7	61
27	The retinal renin–angiotensin system: Roles of angiotensin II and aldosterone. Peptides, 2012, 36, 142-150.	2.4	72
28	Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia, 2011, 54, 2724-2735.	6.3	31